GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Beneish M-Score

bluebird bio (bluebird bio) Beneish M-Score

: 8.70 (As of Today)
View and export this data going back to 2013. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 8.7 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for bluebird bio's Beneish M-Score or its related term are showing as below:

BLUE' s Beneish M-Score Range Over the Past 10 Years
Min: -5.43   Med: -0.73   Max: 48.38
Current: 8.7

During the past 12 years, the highest Beneish M-Score of bluebird bio was 48.38. The lowest was -5.43. And the median was -0.73.


bluebird bio Beneish M-Score Historical Data

The historical data trend for bluebird bio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.43 - - - 0.95

bluebird bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.95 15.32 4.21 8.70

Competitive Comparison

For the Biotechnology subindustry, bluebird bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bluebird bio Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, bluebird bio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where bluebird bio's Beneish M-Score falls into.



bluebird bio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of bluebird bio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4342+0.528 * 16.5857+0.404 * 0.8819+0.892 * 4.226+0.115 * 1.3959
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2213+4.679 * 0.092396-0.327 * 0.9176
=8.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $23.00 Mil.
Revenue was 12.392 + 6.89 + 2.381 + 0.063 = $21.73 Mil.
Gross Profit was 1.437 + -2.674 + -0.995 + 0.042 = $-2.19 Mil.
Total Current Assets was $247.08 Mil.
Total Assets was $613.61 Mil.
Property, Plant and Equipment(Net PPE) was $304.69 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.38 Mil.
Selling, General, & Admin. Expense(SGA) was $149.11 Mil.
Total Current Liabilities was $158.96 Mil.
Long-Term Debt & Capital Lease Obligation was $232.02 Mil.
Net Income was -71.731 + -72.908 + 21.24 + 32.232 = $-91.17 Mil.
Non Operating Income was 10.544 + 9.63 + 102.908 + 6.538 = $129.62 Mil.
Cash Flow from Operations was -61.846 + -72.725 + -86.638 + -56.273 = $-277.48 Mil.
Total Receivables was $12.54 Mil.
Revenue was 0.071 + 1.519 + 1.945 + 1.606 = $5.14 Mil.
Gross Profit was 0.071 + -0.226 + -6.365 + -2.075 = $-8.60 Mil.
Total Current Assets was $160.44 Mil.
Total Assets was $520.10 Mil.
Property, Plant and Equipment(Net PPE) was $300.22 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.06 Mil.
Selling, General, & Admin. Expense(SGA) was $159.41 Mil.
Total Current Liabilities was $126.73 Mil.
Long-Term Debt & Capital Lease Obligation was $234.42 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(23 / 21.726) / (12.535 / 5.141)
=1.058639 / 2.438242
=0.4342

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-8.595 / 5.141) / (-2.19 / 21.726)
=-1.671854 / -0.100801
=16.5857

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (247.076 + 304.689) / 613.608) / (1 - (160.438 + 300.219) / 520.098)
=0.100786 / 0.114288
=0.8819

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21.726 / 5.141
=4.226

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.059 / (6.059 + 300.219)) / (4.38 / (4.38 + 304.689))
=0.019783 / 0.014172
=1.3959

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(149.113 / 21.726) / (159.408 / 5.141)
=6.863343 / 31.007197
=0.2213

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((232.023 + 158.957) / 613.608) / ((234.422 + 126.727) / 520.098)
=0.637182 / 0.694386
=0.9176

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-91.167 - 129.62 - -277.482) / 613.608
=0.092396

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

bluebird bio has a M-score of 8.70 signals that the company is likely to be a manipulator.


bluebird bio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of bluebird bio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


bluebird bio (bluebird bio) Business Description

Traded in Other Exchanges
Address
455 Grand Union Boulevard, Somerville, MA, USA, 02145
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Executives
Richard A Colvin officer: Chief Medical Officer 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain officer: President of SGD C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk officer: Chief Financial Officer 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima officer: Chief Commercial Officer, SGD C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson director 85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio officer: Chief Business & Legal Officer C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman director 1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole officer: SVP, Secy. & General Counsel C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann officer: Chief Regulatory Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton director 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman officer: Chief Financial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten officer: Chief Accounting Officer 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid director 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145